Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely dedicated to vaccines -- to produce two undisclosed vaccine candidates.
"This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and provides additional validation of the benefits of our technology platform," said William Newell, chief executive officer of Sutro Biopharma. "We are looking forward to expanding our expertise in protein expression into the field of vaccines with an established leader in the area."
Details of the partnership were not disclosed. Four Oaks Partners advised Sutro on the transaction.
About Sutro Biopharma
Sutro Biopharma, located in South San Francisco, has developed a cell-free biochemical protein synthesis platform that enables the rapid design, engineering, testing, and scalable production of novel proteins, including those containing site-specific modifications and non-natural amino acids. Sutro's platform allows the rapid and systematic exploration of many protein variants to identify drug and vaccine candidates. Once product candidates are identified, production can be rapidly and predictably scaled up to commercial levels. Sutro has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform. Using this platform, Sutro is collaborating with pharmaceutical and biotech companies to discover and develop novel vaccines, peptide-based therapeutics, antibody drug conjugates, and bifunctional antibodies to meet unmet medical needs. These products will significantly extend the clinical impact of current approaches and are beyond what can be envisioned with current cell-based expression technologies. For more information, visit www.sutrobio.com.
SOURCE Sutro Biopharma
Released January 3, 2013